ZDHHC3 and central nervous system cancer: Recently, the application of targeting S-palmitoylation in cancer therapy has been widely studied, for instance, genetic inhibition of ZDHHC family members (e.g., ZDHHC3, ZDHHC5, ZDHHC17, ZDHHC9, and ZDHHC12) have shown promising and enhanced anticancer effects in colon cancer, breast cancer, non-small cell lung cancer, glioma, leukemia, and ovarian cancer [23–30], while genetic activation of ZDHHC13 exhibits protective effects in skin cancer [31].